Stockreport

SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML

SELLAS Life Sciences Group, Inc.  (SLS) 
Last sellas life sciences group, inc. earnings: 11/14 04:41 pm Check Earnings Report
PDF - 30 Patients Relapsed or Refractory to Venetoclax-Based Regimens Enrolled Ahead of Schedule - - Overall Response Rate (ORR) of 33% and 50% Achieved to Date in 60 mg QW [Read more]